Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review

被引：0
作者：
Tarek Assi
Carine Ngo
Matthieu Faron
Benjamin Verret
Antonin Lévy
Charles Honoré
Clémence Hénon
Cécile Le Péchoux
Rastilav Bahleda
Axel Le Cesne
机构：
[1] Gustave Roussy Cancer Campus,Sarcoma Unit, Department of Cancer Medicine
[2] Oncostat U1018,undefined
[3] Inserm,undefined
[4] Université Paris-Saclay,undefined
[5] Equipe Labellisée Ligue Contre le Cancer,undefined
来源：
Current Treatment Options in Oncology | 2023年 / 24卷
关键词：
Liposarcoma; Soft tissue; Sarcoma; Pleomorphic; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The therapeutic approach of pleomorphic liposarcoma (PLPS), a rare high-grade subgroup of soft tissue sarcoma, is commonly extrapolated from the management of other LPS subtypes. Only published retrospective data on PLPS currently serve as a guide for oncologists without clear recommendations or specific guidelines. In the advanced setting, specific systemic therapy such as eribulin and trabectedin showed promising activity in comparison to conventional therapy (doxorubicin- and gemcitabine-based protocols), which currently remains the current standard of care at initial stages of the disease. The better understanding of soft tissue sarcoma (STS) pathophysiology and disease course has led to the development of adapted clinical trial designs for rare STS histotypes with specific treatment approach.
引用
收藏
页码：1598 / 1613
页数：15
相关论文
共 453 条
  • [71] Miettinen M(2014)Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 3898-86
  • [72] Enzinger FM(2016)PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma J Clin Oncol 34 1089-3132
  • [73] Creytens D(2017)Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial Lancet Oncol 18 1397-4647
  • [74] Folpe AL(2017)Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Lancet Oncol 18 416-511
  • [75] Koelsche C(2018)Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Lancet Oncol 19 1493-1416
  • [76] Mentzel T(2017)Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Lancet Oncol 18 93-543
  • [77] Ferdinande L(2018)Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial JAMA Oncol. 4 4843-36
  • [78] van Gorp JM(2013)Radiotherapy of human sarcoma promotes an intratumoral immune effector signature Clin Cancer Res 19 1879-7833
  • [79] Barretina J(2012)Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 379 3126-undefined
  • [80] Taylor BS(2009)Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043) J Clin Oncol 27 4640-undefined
3456789101112